Echo Therapeutics announced today the issuance of patents covering its Prelude® SkinPrep System for transdermal drug delivery, as well as a notice of allowance for a patent for its Symphony® tCGM System, a non-invasive, wireless, transdermal continuous glucose monitoring system.
Patent approval extends the company's current patent portfolio, which is comprised of six U.S. patents; more than 60 foreign patents; and more than 30 patent applications pending, both in the U.S. and abroad.
"The issuance of these patents further broadens Echo's already extensive intellectual property portfolio surrounding Prelude and Symphony and represents a valuable asset for Echo," Patrick Mooney, M.D., Echo's chairman and CEO stated in the press release. "Furthermore, we expect additional U.S. and foreign patents to issue this year that will provide our products with long-term market value and will add significantly to our shareholder value."
The company's patents, entitled "Skin Permeation Device for Analyte Sensing or Transdermal Drug Delivery," are issued in Australia, Hong Kong, New Zealand, Russia, and 34 European countries, and include claims that encompass the Prelude SkinPrep System. These patents are set to expire in 2028.
The company also received a notice of allowance for U.S. patent application entitled "System and Method for Analyte Sampling and Analysis with Hydrogel." The patent, when issued, is expected to expire in 2026.
Visit our website at www.echotx.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html